Clinical Information

High-risk PCI under support of a pulsatile left ventricular assist device – first German experience with the iVAC 2L system

In 17 patients (3 female, age 73±9 years, left ventricular ejection fraction (LVEF) 45±12%) high-risk PCI (complex left main PCI n=8, PCI of last remaining vessel n=1, complex PCI in severe three-vessel disease and reduced LVEF n=8) was performed underuse of the iVAC 2L system, a new trans-femoral pulsatile assist device with up to 2l additional cardiac output. Before and after device placement as well as immediately after PCI aortic and intracoronary pressure data were collected Click Here for a full report – ivcdgk2018_16-9finalMAC  Click Here download publication – IVACTCTPOSTERWindows

First successful prevention of cardiopulmonary resuscitation during high-risk percutaneous coronary intervention by use of a pulsatile left ventricular assist device: baptismof fire of the iVAC 2L device

A case report published in “European Heart Journal” by Alexander Samol*, Stefanie Schmidt, Melanie Zeyse, and Marcus Wiemer Department of Cardiology and Critical Care Medicine, Johannes Wesling University Hospital, Ruhr University Bochum, Hans-Nolte-Str. 1, 32429 Minden, Germany Received 8 October 2017; accepted 2 January 2018 iVAC2L2 – case report 2 Germany

The PulseCath iVAC 2L left ventricular assist device: conversion to a percutaneous transfemoral approach

Abstract Aims: This technical report describes the essentials and practical implantation technique of the completely percutaneous PulseCath iVAC 2L left ventricular assist device. Methods and results: Percutaneously inserted mechanical left ventricular assist devices are used for circulatory support during cardiogenic shock or high-risk percutaneous coronary interventions. The PulseCath concept is a novel pulsatile design that consists of an extracorporeal membrane pump connected to a largebore catheter which is inserted across the aortic valve retrogradely into the left ventricle. A genuine intraaortic balloon pump (IABP) console drives the pulsatile pump. Conclusions: The percutaneous PulseCath iVAC 2L is driven by a genuine IABP console and provides more left ventricular support. 90th_issue-article_168

Pulsatile iVAC 2L circulatory support in high-risk percutaneous coronary intervention

Abstract Aims: Our aim was to test the feasibility and safety of the transfemoral PulseCath iVAC 2L (PulseCath, Amsterdam, The Netherlands). Methods and results: Circulatory support devices are helpful adjunctive tools to perform high-risk percutaneous coronary interventions (PCI). The PulseCath iVAC 2L is a novel pulsatile circulatory support system capable of generating output of up to 2 L/min. We performed a prospective clinical pilot study enrolling 14 patients who underwent high-risk PCI under protection with the iVAC 2L. Median age was 74 (56-84) years. Implantation of the iVAC 2L was successful in 13 (93%) patients. Median device flow was 1.4 (1.1-2.0) L/min. Total support time was 67 (23-149) minutes. The use of iVAC 2L support was associated with a better mean arterial pressure and cardiac output during the procedure. Angiographic success was 100%. There was one major procedural complication related to the 19 Fr access sheath. There were no major adverse events at three-month follow-up. Conclusions: Circulatory support […]

iVAC 3L Used in Conjunction with ECMO

Left Ventricular Decompression During Peripheral Extracorporeal Membrane Oxygenation Support With the Use of the Novel iVAC Pulsatile Paracorporeal Assist Device  iVAC 3L with ECMO